By implementing FTD patient-specific neuronal models (Iovino et al., 2015; Silva et al., 2016, 2020; Wray, 2017; Jiang et al., 2018; Nakamura et al., 2019; Silva and Haggarty, 2020), we previously reported the first, non-peptidic, tau-selective degrader QC-01-175, developed for target validation and to aid phenotypic characterization of the consequences of targeted degradation in a tauopathy disease context (Silva et al., 2019). Here, MAPT is linked to tauopathy.